Last reviewed · How we verify
Janssen-Cilag Ltd.,Thailand — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| TTS-fentanyl | TTS-fentanyl | marketed | ||||
| Tramadol HCI/acetaminophen | Tramadol HCI/acetaminophen | marketed | Opioid analgesic combination | Mu opioid receptor, norepinephrine transporter, serotonin transporter, COX inhibition | Pain Management | |
| Oxybutinin Extended-Release | Oxybutinin Extended-Release | marketed | Anticholinergic agent | Muscarinic acetylcholine receptor (M3) | Urology |
Therapeutic area mix
- Pain Management · 1
- Urology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- University of California, Davis · 2 shared drug classes
- Albert Einstein College of Medicine · 1 shared drug class
- Edgar LeClaire, MD · 1 shared drug class
- Barrie Urology Associates · 1 shared drug class
- Children's Hospitals and Clinics of Minnesota · 1 shared drug class
- Daewon Pharmaceutical Co., Ltd. · 1 shared drug class
- Alza Corporation, DE, USA · 1 shared drug class
- Albany Medical College · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Janssen-Cilag Ltd.,Thailand:
- Janssen-Cilag Ltd.,Thailand pipeline updates — RSS
- Janssen-Cilag Ltd.,Thailand pipeline updates — Atom
- Janssen-Cilag Ltd.,Thailand pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Janssen-Cilag Ltd.,Thailand — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-cilag-ltd-thailand. Accessed 2026-05-18.